Beta Drugs LtdQ1 FY25Pharmaceuticals & Biotechnology

Beta Drugs Ltd

Q1 FY25 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Revenue guidance

Category 2

→Company aims to grow at a rate between 23%-30% annually across key segments.
→Domestic own branded business expected to continue 25%+ growth.
→CDMO business expected to grow 5%-10% annually.
→Exports are targeted to triple sales in next 2-3 years, with increased margins as regulated market approvals come through.
→Dermatology (Derma) segment expected to grow from Rs. 12.3 crores to Rs. 30 crores next year and Rs. 45-50 crores in 3 years.
→Consolidated revenue guidance for FY26 is around Rs. 450 crores, with a vision to reach Rs. 750 crores by FY28.
→New product launches (e.g., NDDS, Oral Therapy) and expansions in regulated markets expected to fuel growth.
→Expected positive EBITDA in Dermatology from FY26 onwards.
→International markets, including Mexico, Brazil, Philippines, expected to contribute strong growth in coming years.

Category 3

→Beta Drugs projects a consolidated revenue growth rate of approximately 23% to 30% annually, targeting around 25% growth next year.
→The Company aims to multiply and double branded sales in the next 3 years, with export sales expected to triple over 2-3 years.
→EBITDA margins are expected to be stable around 23% to 25% consolidated.
→The Dermatology segment, currently running at a loss, is expected to break even by FY '26 and grow to Rs. 45-50 crores in sales in 3 years.
→The Company forecasts consolidated revenue to reach approximately Rs. 750 crore by 2027-28.
→Net profit rose from Rs. 36.43 crore to Rs. 45.83 crore in FY '25 excluding one-time expenses.
→The focus remains on sustainable growth, balancing topline and bottom-line improvements with margin stability.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Beta Drugs Ltd and 1,400+ other companies.

→The company recently raised approximately Rs. 117 crores through a preferential issue involving convertible debentures, which carry a coupon leading to higher interest costs.
→As of now, the funds from this issuance are largely parked in fixed deposits, with around Rs. 11 crores utilized for facility upgrades.
→There is no mention of any immediate new fundraising plans through debt or equity.
→The management is exploring growth opportunities, including possible M&A, but currently, there is nothing concrete on the table.
→Expansions planned include new corporate building for regulatory and R&D functions, and intermediate manufacturing capacity.
→The company seems well capitalized with a healthy cash position, focusing on utilizing existing raised funds for growth and expansion rather than raising new funds immediately.

→The document does not explicitly mention the current or expected order book or pending orders in numeric terms.
→Rahul Batra mentions robust business operations with multiple strategic growth plans, indicating strong future demand.
→CDMO segment has about 30 clients, with 3 new clients added this year, suggesting ongoing and future order inflows.
→The company is actively preparing dossiers for regulatory approvals in multiple export markets (Mexico, Brazil, Thailand, Philippines, Vietnam), indicative of pending orders and potential new market entries.
→Transition to Mainboard and capital investments (e.g., new corporate office, API intermediate plant search) demonstrate readiness to handle increased order volumes.
→Management emphasizes a robust pipeline for the next 3-4 years and consistent growth of 23%-30% annually across segments, signifying a positive outlook on order inflow.

Yes

→Major current capex includes building a new corporate office that will house regulatory, R&D, and other teams in one place.
→Investment of approximately Rs. 11 crores has been made in facility upgrades, mainly in Adley Formulations and Adley Lab.
→The Company is actively looking for land or a plant for backward integration to manufacture intermediates, reducing dependency on China and ensuring a reliable supply chain for KSMs.
→R&D team has around 10 people currently, with ongoing investment in scientific and drug delivery system innovations.
→Potential strategic investments/M&A will be considered if good branded businesses become available, though there is nothing concrete on the table currently.
→Funds of around Rs. 117 crores raised remain largely parked in FDs, with selective utilization ongoing as opportunities arise.

How does Beta Drugs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Beta Drugs Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Beta Drugs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.